Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer, Xeris uses these filings to report financial results, describe product performance for Recorlev, Gvoke, and Keveyis, and update investors on developments in its pipeline and technology platforms, including XP-8121 and the XeriSol and XeriJect technologies.
Key documents for XERS include current reports on Form 8-K, which Xeris uses to furnish press releases detailing quarterly and year-to-date results, revenue by product, cost of goods sold, research and development spending, selling, general and administrative expenses, and non-GAAP measures such as Adjusted EBITDA. These filings also summarize business highlights, such as changes in demand across the company’s commercial products, updates to revenue guidance, and commentary on investments in Recorlev commercialization and pipeline advancement.
In addition to 8-Ks, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q for a more comprehensive view of Xeris’ business, including risk factors, segment information, and detailed financial statements. Proxy statements and other filings can provide information on governance and compensation, while ownership and insider transaction reports on forms such as Form 4 can show equity awards and trading activity by directors and officers.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, product performance, and key disclosures without reading every page. Real-time updates from EDGAR help ensure that new XERS filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 reports, are available as they are posted, giving investors a structured way to review Xeris’ regulatory history and ongoing reporting.
Xeris Biopharma Holdings, Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on June 4, 2026 at 8:00 a.m. Central Time. Shareholders of record on April 14, 2026, when 172,625,762 common shares were outstanding, are entitled to vote.
Investors will elect two Class II directors to serve until 2029, ratify Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approve on a non-binding advisory basis the compensation of named executive officers. The board recommends voting in favor of all three proposals.
The meeting will be held entirely online via www.proxydocs.com/XERS, with advance registration required by June 3, 2026. The proxy describes board structure, committee responsibilities, director independence, director compensation, and corporate governance policies, including stock ownership guidelines and a code of business conduct and ethics.
Xeris Biopharma Holdings, Inc. reported that Dr. Jeffrey Sherman will retire from its Board of Directors and will not stand for reelection at the 2026 Annual Meeting of Stockholders. He has served as a director since 2021 and sits on the Compensation Committee and the Nominating and Corporate Governance Committee.
The company stated that Dr. Sherman’s decision is not due to any disagreement regarding operations, policies, or practices. When his term ends at the 2026 Annual Meeting, the Board size will be reduced from eight to seven directors.
Xeris Biopharma Holdings, Inc. officer Beth Hecht reported an open-market sale of 16,667 shares of common stock at a weighted average price of $5.9914 per share. After this transaction, she directly owns 1,209,840 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
Xeris Biopharma Holdings director Brady James Aloysius sold 10,834 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $5.5414 per share under a Rule 10b5-1 trading plan. Following the sale, he directly holds 89,166 shares. The sale price reflects multiple trades in a range from $5.29 to $5.63 per share.
Xeris Biopharma Holdings Inc: The Vanguard Group filed Amendment No. 2 to a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the class following an internal realignment. The filing states certain Vanguard subsidiaries will report disaggregated holdings after the January 12, 2026 realignment.
The cover identifies the issuer address and CUSIP and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing describes that Vanguard no longer is deemed to beneficially own securities held by the listed subsidiaries in reliance on SEC Release No. 34-39538.
Xeris Biopharma Holdings, Inc. officer Kevin McCulloch exercised stock options to acquire a total of 48,898 shares of common stock on March 12, 2026, at exercise prices of $4.09 and $3.94 per share. These options were granted under the company’s 2018 Stock Option/Stock Issuance Plan and had fully vested based on prior service conditions. Following the transactions, he holds 1,777,725 common shares directly and 25,000 shares indirectly through his spouse. The filing notes he disclaims beneficial ownership of some reported securities beyond his pecuniary interest.
Xeris Biopharma Holdings reported that officer Steven Pieper exercised stock options and acquired common shares. On March 5, 2026, he converted options into 27,891 common shares at $4.09 per share and 14,036 common shares at $5.93 per share through derivative exercises.
These options were originally granted on January 31, 2018 and December 10, 2020 under company stock option plans with vesting tied to continued employment. Following the transactions, he directly owned up to 1,408,940 common shares.
Xeris Biopharma Holdings, Inc. reported that company officer Beth Hecht executed two open-market sales of its common stock under a pre-established Rule 10b5-1 trading plan. She sold a total of 16,667 shares on March 2, 2026, at prices including $6.2401 and $7.06 per share, and held 1,226,507 shares afterward.